In conclusion, diabetes caused by the heterozygous pathogenic variant R46Q in the insulin gene may be well treated on noninsulin regimens, in particular with agents that reduce the demand for endogenous insulin secretion. The gene discussed is INS; the disease is diabetes mellitus.